An array of Chinese drug makers showcased positive trial results for new cancer treatments at a major European medical conference, underscoring the expanding international influence of China’s biotech sector.
Domestic innovative drugs, particularly antibody-drug conjugates (ADCs), delivered impressive data across multiple tumour types at the European Society for Medical Oncology (Esmo) Congress, with some early-stage data further showing the country’s “innovation capabilities”, said analysts from China Post Securities in a note on Monday.
Chinese research accounted for 29 of 96 late-breaking abstracts (LBAs) – summaries of newly available clinical research data – presented at the prominent industry conference, held in Madrid from October 23 to 27. Five of the 12 studies selected for the prestigious presidential symposium were also from Chinese firms.